Skip to main content

Week in Review: $1.2 Billion in China Life Science Deals, IPOs and Financings

Deals and Financings   A Sino Biopharma subsidiary out-licensed ex-China rights for a fibrosis therapy to Graviton Bio of New York in a deal worth up to $517.5 million; Yangtze River Pharma signed a $338 million deal for China rights to a gastroesophageal reflux treatment from South Korea 's Daewoong Pharma; Connect Biopharma, a Suzhou-San Diego company, raised $191 million in a NASDAQ IPO to support its portfolio of autoimmune treatments; Hansoh Pharma entered an $122 million agreement to acquire Greater China rights to a novel antifungal from Synexis of New Jersey; Shanghai 's Hanyu Medical completed a $77 million D+ funding for its minimally invasive mitral valve device, ValveClamp; Shanghai WuXi Biologics will acquire a 90% interest in a Suzhou CDMO backed by CBC Group and will collaborate to develop biologics for CBC portfolio companies; WuXi Biologics also bought a biotech drug manufacturing facility in Hangzhou from Pfizer China that had been manufacturing biosimilars; Hangzhou Chance Pharma acquired greater China rights for an inhaled drug aimed at pulmonary arterial hypertension from US-based Aerami Therapeutics; BeiGene will collaborate with Shanghai 's 111 Inc. to develop internet based retail drug delivery and patient management services; Industry Insights   Two months into 2021, the momentum from 2020's record-setting levels of China life science activity has continued into the new year; Trials and Approvals   Harbour BioMed dosed the first patient in the China arm of a global Phase III trial of a novel treatment for moderate-to-severe dry eye disease; Adagene, a Suzhou-San Francisco immunotherapy company, started a global Phase I trial of a novel CTLA-4 mAb to treat solid tumors. Stock Symbols: (HK: 1177) (NSDQ: CNTB) (HK: 3692) (NSDQ: SCYX) (HK: 2269) (NSDQ: BGNE; HK:06160) (NSDQ: YI) (HK: 02142) (NSDQ: ADAG) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.